Giede-Jeppe, Antje
Gerner, Stefan T.
Sembill, Jochen A.
Kuramatsu, Joji B.
Lang, Stefan
Luecking, Hannes
Staykov, Dimitre
Huttner, Hagen B.
Volbers, Bastian
Funding for this research was provided by:
Friedrich-Alexander-Universität Erlangen-Nürnberg
Article History
Received: 2 February 2023
Accepted: 20 October 2023
First Online: 29 November 2023
Conflict of Interest
: Prof. Huttner reports research grants by Novartis, Medtronic, UCB Pharma, and Portola Pharmaceuticals. HBH reports personal fees from Bayer AG, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, CLS Behring, UCB Pharma, and Portola Pharmaceuticals. Dr. Volbers reports personal fees from Pfizer AG/Bristol-Myers Squibb SA, personal fees from Bayer AG, grants from institutional grant (Inselspital), personal fees from Ipsen Pharma, personal fees from CSL Behring, outside the submitted work. The remaining authors have no conflicts of interest to disclose.
: Ethical approval was obtained by the institutional ethics committee.